Immunic (IMUX) News Today $1.03 -0.06 (-5.50%) (As of 05:44 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Immunic, Inc. (NASDAQ:IMUX) Receives Consensus Recommendation of "Buy" from AnalystsShares of Immunic, Inc. (NASDAQ:IMUX - Get Free Report) have received an average recommendation of "Buy" from the seven ratings firms that are currently covering the company, Marketbeat.com reports. Five analysts have rated the stock with a buy recommendation and two have issued a strong buy recomDecember 18 at 4:26 AM | marketbeat.comImmunic, Inc. (NASDAQ:IMUX) Sees Large Increase in Short InterestImmunic, Inc. (NASDAQ:IMUX - Get Free Report) saw a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 4,190,000 shares, an increase of 10.3% from the November 15th total of 3,800,000 shares. Based on an average daily trading volume, of 885,100 shares, the days-to-cover ratio is currently 4.7 days.December 15 at 9:40 AM | marketbeat.comImmunic, Inc. (NASDAQ:IMUX) Shares Sold by Janus Henderson Group PLCJanus Henderson Group PLC lowered its holdings in Immunic, Inc. (NASDAQ:IMUX - Free Report) by 27.9% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,099,278 shares of the company's stock after selling 1,974,566 shares during the periodDecember 9, 2024 | marketbeat.comB. Riley Estimates Immunic's FY2024 Earnings (NASDAQ:IMUX)Immunic, Inc. (NASDAQ:IMUX - Free Report) - Stock analysts at B. Riley lowered their FY2024 earnings per share estimates for shares of Immunic in a research note issued to investors on Tuesday, November 26th. B. Riley analyst W. Wood now forecasts that the company will post earnings per share ofNovember 28, 2024 | marketbeat.comAnalysts Offer Predictions for Immunic FY2024 EarningsImmunic, Inc. (NASDAQ:IMUX - Free Report) - Research analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of Immunic in a research report issued on Monday, November 25th. HC Wainwright analyst M. Caufield forecasts that the company will post earnings of ($0.November 27, 2024 | marketbeat.comEQS-News: Immunic, Inc. to Participate in Investor Conference in DecemberNovember 26, 2024 | markets.businessinsider.comImmunic initiated with a Buy at H.C. WainwrightNovember 26, 2024 | markets.businessinsider.comHC Wainwright & Co. Initiates Coverage of Immunic (IMUX) with Buy RecommendationNovember 26, 2024 | msn.comImmunic’s Promising Pipeline Progress and Stable Financials Justify Buy RatingNovember 26, 2024 | markets.businessinsider.comQ4 Earnings Estimate for Immunic Issued By HC WainwrightImmunic, Inc. (NASDAQ:IMUX - Free Report) - Equities research analysts at HC Wainwright issued their Q4 2024 earnings per share estimates for Immunic in a research note issued to investors on Monday, November 25th. HC Wainwright analyst M. Caufield forecasts that the company will earn ($0.25) perNovember 26, 2024 | marketbeat.comImmunic, Inc. to Participate in Investor Conference in DecemberNovember 26, 2024 | prnewswire.comHC Wainwright Initiates Coverage on Immunic (NASDAQ:IMUX)HC Wainwright started coverage on shares of Immunic in a report on Monday. They set a "buy" rating and a $10.00 price objective for the company.November 25, 2024 | marketbeat.comImmunic, Inc. (NASDAQ:IMUX) Receives Average Recommendation of "Buy" from BrokeragesShares of Immunic, Inc. (NASDAQ:IMUX - Get Free Report) have been assigned an average rating of "Buy" from the six research firms that are covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a buy recommendation and two have given a strong buy rNovember 23, 2024 | marketbeat.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Fulcrum Therapeutics (FULC) and Immunic (IMUX)November 19, 2024 | markets.businessinsider.comImmunic's IMU-856 shows potential in gastrointestinal health trials - ICYMINovember 16, 2024 | proactiveinvestors.comImmunic, Inc. (NASDAQ:IMUX) Short Interest UpdateImmunic, Inc. (NASDAQ:IMUX - Get Free Report) saw a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 4,500,000 shares, a growth of 29.7% from the October 15th total of 3,470,000 shares. Based on an average daily trading volume, of 704,000 shares, the days-to-cover ratio is presently 6.4 days.November 15, 2024 | marketbeat.comRichard Alan Rudick Acquires 87,300 Shares of Immunic, Inc. (NASDAQ:IMUX) StockNovember 14, 2024 | insidertrades.comImmunic announces publication of IMU-856 dataNovember 13, 2024 | markets.businessinsider.comImmunic reports positive Phase 1 results for celiac disease therapy published in The LancetNovember 13, 2024 | proactiveinvestors.comImmunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & HepatologyNovember 13, 2024 | prnewswire.comOptimistic Buy Rating for Immunic Driven by Promising Trials and Market Opportunities for VidoCaNovember 13, 2024 | markets.businessinsider.comImmunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic Progress Amid Financial ChallengesNovember 9, 2024 | finance.yahoo.comImmunic, Inc. (IMUX) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | seekingalpha.comEQS-News: Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 8, 2024 | markets.businessinsider.comImmunic, Inc. Advances MS Trials Amid Financial UpdateNovember 8, 2024 | markets.businessinsider.comImmunic highlights progress in multiple sclerosis programs, targets 2025 milestonesNovember 7, 2024 | proactiveinvestors.comImmunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 7, 2024 | prnewswire.comImmunic Q3 2024 Earnings PreviewNovember 7, 2024 | msn.comImmunic (IMUX) to Release Earnings on ThursdayImmunic (NASDAQ:IMUX) will be releasing earnings before the market opens on Thursday, November 7, Zacks reports.November 1, 2024 | marketbeat.comImmunic (IMUX) Scheduled to Post Earnings on ThursdayImmunic (NASDAQ:IMUX) will be releasing earnings before the market opens on Thursday, November 7, Zacks reports.November 1, 2024 | marketbeat.comImmunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate UpdateOctober 31, 2024 | prnewswire.comEQS-News: Immunic to Participate in Industry, Scientific and Investor Conferences in NovemberOctober 29, 2024 | markets.businessinsider.comImmunic to Participate in Industry, Scientific and Investor Conferences in NovemberOctober 29, 2024 | prnewswire.comImmunic, Inc. (NASDAQ:IMUX) Receives Consensus Recommendation of "Buy" from BrokeragesImmunic, Inc. (NASDAQ:IMUX - Get Free Report) has been given an average rating of "Buy" by the seven brokerages that are presently covering the firm, Marketbeat reports. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The aveOctober 29, 2024 | marketbeat.comImmunic, Inc. (NASDAQ:IMUX) Sees Large Growth in Short InterestImmunic, Inc. (NASDAQ:IMUX - Get Free Report) was the recipient of a large growth in short interest in the month of October. As of October 15th, there was short interest totalling 3,470,000 shares, a growth of 29.5% from the September 30th total of 2,680,000 shares. Based on an average trading volume of 576,100 shares, the days-to-cover ratio is presently 6.0 days.October 28, 2024 | marketbeat.comPromising Phase 3 Trial Results and Strategic Insights Drive Buy Rating for Vidofludimus CalciumOctober 25, 2024 | markets.businessinsider.comImmunic announces outcome of ENSURE programOctober 22, 2024 | markets.businessinsider.comImmunic late-stage program for lead asset to proceed as plannedOctober 22, 2024 | msn.comImmunic Phase 3 MS study advances following positive recommendation from independent committeeOctober 22, 2024 | proactiveinvestors.comImmunic Shares Up 12% on Positive MS Drug AnalysisOctober 22, 2024 | marketwatch.comImmunic Announces Positive Outcome From Interim Futility Analysis Of Phase 3 ENSURE ProgramOctober 22, 2024 | markets.businessinsider.comImmunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple SclerosisOctober 22, 2024 | prnewswire.comFY2024 EPS Estimates for Immunic Decreased by AnalystImmunic, Inc. (NASDAQ:IMUX - Free Report) - Research analysts at Brookline Capital Management reduced their FY2024 earnings per share estimates for shares of Immunic in a report released on Tuesday, October 15th. Brookline Capital Management analyst T. Bussian now expects that the company will eaOctober 18, 2024 | marketbeat.comBrookline Capital Management Comments on Immunic, Inc.'s Q4 2025 Earnings (NASDAQ:IMUX)Immunic, Inc. (NASDAQ:IMUX - Free Report) - Stock analysts at Brookline Capital Management issued their Q4 2025 earnings per share (EPS) estimates for shares of Immunic in a note issued to investors on Tuesday, October 15th. Brookline Capital Management analyst T. Bussian forecasts that the compaOctober 17, 2024 | marketbeat.comShort Interest in Immunic, Inc. (NASDAQ:IMUX) Increases By 14.0%Immunic, Inc. (NASDAQ:IMUX - Get Free Report) saw a large growth in short interest during the month of September. As of September 30th, there was short interest totalling 2,680,000 shares, a growth of 14.0% from the September 15th total of 2,350,000 shares. Based on an average daily volume of 390,200 shares, the short-interest ratio is currently 6.9 days.October 16, 2024 | marketbeat.comRenaissance Technologies LLC Has $323,000 Holdings in Immunic, Inc. (NASDAQ:IMUX)Renaissance Technologies LLC decreased its stake in shares of Immunic, Inc. (NASDAQ:IMUX - Free Report) by 61.0% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 291,087 shares of the company's stock after selling 456,184 shares during the pOctober 12, 2024 | marketbeat.comImmunic Inc (IMUX) Q2 2024 Earnings Call Highlights: Promising Clinical Data and Financial ...October 9, 2024 | finance.yahoo.comImmunic, Inc. (NASDAQ:IMUX) Receives Average Rating of "Buy" from AnalystsImmunic, Inc. (NASDAQ:IMUX - Get Free Report) has received a consensus recommendation of "Buy" from the seven brokerages that are currently covering the firm, Marketbeat reports. Five research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation toOctober 4, 2024 | marketbeat.comB. Riley Reacts to Immunic’s Update on Clinical Benefits of Vidofludimus CalciumOctober 1, 2024 | msn.comImmunic’s MS Drug Candidate Shows Promising Future: A Comprehensive Buy Rating JustificationSeptember 24, 2024 | markets.businessinsider.com Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)It’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life-changing for those who are prepared. Why? Because altcoin prices are about to explode. >> Register for the Workshop Now IMUX Media Mentions By Week IMUX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMUX News Sentiment▼0.470.54▲Average Medical News Sentiment IMUX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMUX Articles This Week▼23▲IMUX Articles Average Week Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Akebia Therapeutics News Alumis News Cryoport News Alvotech News Neurogene News Contineum Therapeutics News biote News Voyager Therapeutics News Design Therapeutics News Tango Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMUX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMUX Stock Alerts